Key features and details
- Rat monoclonal [PyMT] to Polyoma virus, Medium T antigen
- Suitable for: IP, ICC/IF, WB
- Isotype: IgG2b
Product nameAnti-Polyoma virus, Medium T antigen antibody [PyMT]
DescriptionRat monoclonal [PyMT] to Polyoma virus, Medium T antigen
Tested applicationsSuitable for: IP, ICC/IF, WBmore details
Species reactivityReacts with: Other species
Synthetic peptide (N terminal).
Binds medium T antigen only, allows isolation of viral T antigens.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferConstituent: PBS
Concentration information loading...
Primary antibody notesBinds medium T antigen only, allows isolation of viral T antigens.
Our Abpromise guarantee covers the use of ab15085 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent dilution.|
|ICC/IF||Use at an assay dependent dilution.|
|WB||Use at an assay dependent concentration.|
RelevanceMiddle T antigen (MT) is a 421-amino-acid protein associated with membranes and underlying cytoskeletal elements, and is associated with a tyrosine-specific protein kinase activity. It is the principal oncoprotein of polyomavirus that is necessary and often sufficient for transformation in vitro. MT delivered as a transgene or a retrovirus can induce tumors in a wide variety of tissues. Polyomavirus (PyV) is a small, double-stranded, closed-circular-DNA virus with an approximately 5-kb genome divided into two roughly equal regions. The late transcripts produce the viral capsid proteins, whereas the early region encodes three so-called tumor (T) antigens that are important for both productive infection and transformation.
Cellular localizationCytoplasmic location in cells infected with virus.
- Middle T antigen antibody
- MT AG antibody
- MT antibody
- Polyoma virus middle t antigen antibody
ab15085 has been referenced in 13 publications.
- Kim J et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet 50:1705-1715 (2018). PubMed: 30349115
- Messenheimer DJ et al. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Clin Cancer Res 23:6165-6177 (2017). PubMed: 28855348
- Thienpont B et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537:63-68 (2016). IF . PubMed: 27533040
- Kim J et al. Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways. Cancer Res 76:6424-6435 (2016). ICC/IF . PubMed: 27569213
- Roy A et al. Targeting Serglycin Prevents Metastasis in Murine Mammary Carcinoma. PLoS One 11:e0156151 (2016). PubMed: 27223472